Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 532

1.

Non-steroidal anti-inflammatory drug use and the risk of benign prostatic hyperplasia-related outcomes and nocturia in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

Sutcliffe S, Grubb Iii RL, Platz EA, Ragard LR, Riley TL, Kazin SS, Hayes RB, Hsing AW, Andriole GL; Urologic Diseases in America Project.

BJU Int. 2012 Oct;110(7):1050-9. doi: 10.1111/j.1464-410X.2011.10867.x. Epub 2012 Mar 19.

2.

Sexually transmitted infections, benign prostatic hyperplasia and lower urinary tract symptom-related outcomes: results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.

Breyer BN, Huang WY, Rabkin CS, Alderete JF, Pakpahan R, Beason TS, Kenfield SA, Mabie J, Ragard L, Wolin KY, Grubb RL 3rd, Andriole GL, Sutcliffe S.

BJU Int. 2016 Jan;117(1):145-54. doi: 10.1111/bju.13050. Epub 2015 Apr 23.

3.

The role of BPH, lower urinary tract symptoms, and PSA levels on erectile function of Brazilian men who undergo prostate cancer screening.

Antunes AA, Srougi M, Dall'oglio MF, Vicentini F, Paranhos M, Freire GC.

J Sex Med. 2008 Jul;5(7):1702-7. doi: 10.1111/j.1743-6109.2007.00713.x.

PMID:
18194186
4.

Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study.

Sacco E, Bientinesi R, Marangi F, Totaro A, D'Addessi A, Racioppi M, Pinto F, Vittori M, Bassi P.

BJU Int. 2012 Dec;110(11 Pt C):E837-44. doi: 10.1111/j.1464-410X.2012.11288.x. Epub 2012 Jun 19.

5.

Natural history of lower urinary tract symptoms in Japanese men from a 15-year longitudinal community-based study.

Fukuta F, Masumori N, Mori M, Tsukamoto T.

BJU Int. 2012 Oct;110(7):1023-9. doi: 10.1111/j.1464-410X.2011.10866.x. Epub 2012 Jan 11.

6.

Prevalence of BPH and lower urinary tract symptoms in West Africans.

Chokkalingam AP, Yeboah ED, Demarzo A, Netto G, Yu K, Biritwum RB, Tettey Y, Adjei A, Jadallah S, Li Y, Chu LW, Chia D, Niwa S, Partin A, Thompson IM, Roehrborn C, Hoover RN, Hsing AW.

Prostate Cancer Prostatic Dis. 2012 Jun;15(2):170-6. doi: 10.1038/pcan.2011.43. Epub 2011 Sep 13.

PMID:
21912428
7.

Non-steroidal anti-inflammatory drug use and colorectal polyps in the Prostate, Lung, Colorectal, And Ovarian Cancer Screening Trial.

Johnson CC, Hayes RB, Schoen RE, Gunter MJ, Huang WY; PLCO Trial Team.

Am J Gastroenterol. 2010 Dec;105(12):2646-55. doi: 10.1038/ajg.2010.349. Epub 2010 Aug 31.

8.

Can benign prostatic hyperplasia be identified in the primary care setting using only simple tests? Results of the Diagnosis IMprovement in PrimAry Care Trial.

Carballido J, Fourcade R, Pagliarulo A, Brenes F, Boye A, Sessa A, Gilson M, Castro R.

Int J Clin Pract. 2011 Sep;65(9):989-96. doi: 10.1111/j.1742-1241.2011.02735.x. Epub 2011 Jul 7.

PMID:
21733048
9.

EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction.

Gratzke C, Bachmann A, Descazeaud A, Drake MJ, Madersbacher S, Mamoulakis C, Oelke M, Tikkinen KAO, Gravas S.

Eur Urol. 2015 Jun;67(6):1099-1109. doi: 10.1016/j.eururo.2014.12.038. Epub 2015 Jan 19. Review.

PMID:
25613154
10.

[Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association].

Descazeaud A, Robert G, Delongchamps NB, Cornu JN, Saussine C, Haillot O, Devonec M, Fourmarier M, Ballereau C, Lukacs B, Dumonceau O, Azzouzi AR, Faix A, Desgrandchamps F, de la Taille A; Comité des troubles mictionnels de l’homme de l’association française d’urologie.

Prog Urol. 2012 Dec;22(16):977-88. doi: 10.1016/j.purol.2012.10.001. Epub 2012 Nov 6. French.

PMID:
23178093
11.

Physical activity and benign prostatic hyperplasia-related outcomes and nocturia.

Wolin KY, Grubb RL 3rd, Pakpahan R, Ragard L, Mabie J, Andriole GL, Sutcliffe S.

Med Sci Sports Exerc. 2015 Mar;47(3):581-92. doi: 10.1249/MSS.0000000000000444.

12.

Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia.

Roehrborn CG, Boyle P, Gould AL, Waldstreicher J.

Urology. 1999 Mar;53(3):581-9.

PMID:
10096388
13.

Does Prostate Size Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from the REDUCE Trial.

Simon RM, Howard LE, Moreira DM, Roehrborn C, Vidal AC, Castro-Santamaria R, Freedland SJ.

Eur Urol. 2016 May;69(5):885-91. doi: 10.1016/j.eururo.2015.12.002. Epub 2015 Dec 24.

PMID:
26724841
14.

Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.

Schenk JM, Calip GS, Tangen CM, Goodman P, Parsons JK, Thompson IM, Kristal AR.

Am J Epidemiol. 2012 Jul 15;176(2):156-63. doi: 10.1093/aje/kwr524. Epub 2012 Jun 28.

15.
16.

A new experimental rat model of erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: the testosterone-supplemented spontaneously hypertensive rat.

Oudot A, Oger S, Behr-Roussel D, Caisey S, Bernabé J, Alexandre L, Giuliano F.

BJU Int. 2012 Nov;110(9):1352-8. doi: 10.1111/j.1464-410X.2012.11085.x. Epub 2012 Mar 27.

17.

Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.

Roehrborn CG, Nickel JC, Andriole GL, Gagnier RP, Black L, Wilson TH, Rittmaster RS.

Urology. 2011 Sep;78(3):641-6. doi: 10.1016/j.urology.2011.03.063. Epub 2011 Jul 20.

PMID:
21764428
18.

Prostate size, nocturia and the digital rectal examination: a cohort study of 30 500 men.

Stone BV, Shoag J, Halpern JA, Mittal S, Lewicki P, Golombos DM, Bedretdinova D, Chughtai B, Barbieri CE, Lee RK.

BJU Int. 2017 Feb;119(2):298-304. doi: 10.1111/bju.13613. Epub 2016 Aug 23.

19.

Associations between diabetes and clinical markers of benign prostatic hyperplasia among community-dwelling Black and White men.

Sarma AV, Burke JP, Jacobson DJ, McGree ME, St Sauver J, Girman CJ, Lieber MM, Herman W, Macoska J, Montie JE, Jacobsen SJ.

Diabetes Care. 2008 Mar;31(3):476-82. Epub 2007 Dec 10.

PMID:
18071006
20.

[Guide dedicated to general practitioner for the management of lower urinary tract symptoms related to benign prostatic hyperplasia].

Descazeaud A, Barry Delongchamps N, Cornu JN, Azzouzi AR, Buchon D, Benchikh A, Coloby P, Dumonceau O, Fourmarier M, Haillot O, Lebdai S, Mathieu R, Misrai V, Saussine C, de La Taille A, Robert G; Comité des troubles mictionnels de l’homme de l’Association française d’urologie (CTMH-AFU).

Prog Urol. 2015 Jun;25(7):404-12. doi: 10.1016/j.purol.2015.02.008. Epub 2015 Apr 2. French.

PMID:
25841758

Supplemental Content

Support Center